Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
CI Financial Announces Receipt of Interim Court Order and Addition of Holdco Alternative to Plan of Arrangement with Mubadala Capital
CI Financial receives an interim court order concerning the transaction under which CI shares will be acquired by an affiliate of Mubadala Capital.
CI Financial Announces Filing and Mailing of Circular for Special Meeting to Approve Plan of Arrangement with Mubadala Capital
CI Financial Corp. ("CI" or the "Corporation") (TSX: CIX) today announced the commencement of the mailing of its management information circular and related shareholder meeting materials for the special meeting of CI shareholders (the "Meeting") to consider and vote on the Corporation's proposed plan of arrangement (the "Arrangement") with an affiliate of funds managed by Mubadala Capital (the "Purchaser") pursuant to which all of the issued and outstanding shares of CI will be acquired for cash consideration equal to $32.
CI Financial Advances Mubadala Arrangement with Holdco Option
CI Financial Corp. has received an interim court order for its proposed plan of arrangement with Mubadala Capital, allowing the acquisition of its shares for $32.00 per share, excluding those of senior management who opt for equity rollover agreements.
CI Financial gets interim court order for shareholder meeting on Mubadala deal
CI Financial (TSX:CIX:CA) (OTCPK:CIXXF) received an interim order from the Ontario Superior Court of Justice that authorizes, among other things, the special meeting of shareholders, currently scheduled for Feb.
FierceBiotech
2d
Arch-backed Tenvie unveils with $200M and a neuro pipeline with assets from Denali
Tenvie Therapeutics has unveiled with $200 million and the goal of transforming the neurological treatment landscape, nabbing ...
3h
Light Horse emerges with $62m and Novartis partnership worth up to $1bn
Light Horse’s CEO said the biotech’s initial focus will be on “high-value and historically challenging” oncology targets.
STAT
2d
Denali Therapeutics spinout raises $200M as neuro company resets
Tenvie Therapeutics is making hay from an R&D shift at Denali Therapeutics, acquiring several of its neuroscience drug ...
FierceBiotech
20h
Light Horse lassos Novartis partnership worth up to $1B, wrangles $62M series A
Light Horse Therapeutics is off to the races, rounding up a $62 million series A and tacking on a Novartis partnership that ...
BioSpace
2d
Tenvie Debuts With Denali Assets, $200M for Neurological, Metabolic Diseases
Backed by ARCH Venture Partners, F-Prime Capital and Mubadala Capital, the new company will develop a pipeline of ...
STAT
2d
East Asians under-represented in biopharma leadership
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
2d
Tenvie Therapeutics Launches with $200 Million to Deliver Breakthrough Small Molecule Therapies
Advancing a deep pipeline of therapeutics focused on treating neurological, cardiometabolic, and ophthalmic diseasesLed by expert R&D ...
1d
Why biotech startup Tenvie sees promise in drugs from founders' old company
About a year ago, Tenvie President and Chief Scientific Officer Tony Estrada approached Denali CEO Ryan Watts and others in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback